Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Indivior is a specialty pharmaceutical company focused on addiction treatment, primarily opioid use disorder (OUD). The company's core franchise is Sublocade (buprenorphine extended-release injection), which competes in the medication-assisted treatment (MAT) market alongside Suboxone Film (sublingual buprenorphine/naloxone). With 80%+ gross margins and growing operating leverage, Indivior benefits from the structural tailwind of rising OUD prevalence and expanding treatment access, though it faces patent expiration risks and regulatory scrutiny.
Indivior generates revenue through branded specialty pharmaceuticals targeting addiction disorders, primarily sold through specialty pharmacies and treatment centers. Pricing power derives from product differentiation (monthly injectable vs daily sublingual), physician relationships, and patient adherence benefits. Sublocade commands premium pricing ($1,500-2,000 per monthly injection) due to improved compliance and reduced diversion risk versus sublingual formulations. The company operates with minimal manufacturing capex (outsourced production), creating high incremental margins as Sublocade scales. Competitive moat stems from regulatory barriers (REMS programs), established prescriber networks, and switching costs in addiction treatment protocols.
Sublocade prescription volume growth and market share gains versus Suboxone Film and generic buprenorphine products
Patent litigation outcomes for Suboxone Film (generic entry timing directly impacts revenue trajectory)
Regulatory developments affecting opioid treatment access, including DEA prescribing limits and Medicaid/Medicare reimbursement policy
Pipeline progress for next-generation addiction treatments and label expansion opportunities
Legal settlement announcements related to historical marketing practices and opioid litigation exposure
Patent cliff exposure as Suboxone Film faces generic competition, with exclusivity periods expiring and at-risk launches threatening 35-40% of current revenue base
Regulatory risk from DEA prescribing restrictions, REMS program modifications, and potential policy shifts affecting buprenorphine access and reimbursement
Litigation overhang from historical opioid-related marketing practices and potential inclusion in broader opioid settlement frameworks, creating uncertain financial liabilities
Reimbursement pressure as payers scrutinize high-cost injectable formulations versus lower-cost generic sublingual alternatives, requiring robust health economics data
Generic buprenorphine/naloxone sublingual products eroding Suboxone Film franchise with 80-90% price discounts
Competitive long-acting injectable entries (potential biosimilars or novel formulations) targeting Sublocade's premium positioning
Alternative addiction treatment modalities including naltrexone extended-release (Vivitrol) and emerging pharmacotherapies in clinical development
Telehealth-enabled treatment models favoring lower-cost oral formulations over in-office injectable administration
Negative shareholder equity (-$4.3B book value) reflecting accumulated legal settlements and restructuring charges, limiting financial flexibility
Current ratio of 0.71 indicates potential near-term liquidity constraints requiring careful working capital management or refinancing
Debt/Equity ratio of -3.58 (negative equity) obscures true leverage; absolute debt levels and covenant compliance require monitoring
Contingent liabilities from ongoing litigation could require material cash outlays, straining liquidity despite positive operating cash generation
low - Addiction treatment demand is largely non-discretionary and counter-cyclical. Economic stress can increase substance abuse rates while simultaneously constraining patient ability to pay. However, government programs (Medicaid, Medicare) fund majority of treatment, insulating revenue from consumer spending cycles. Opioid epidemic trends and policy responses drive demand more than GDP growth. Treatment capacity expansion and destigmatization efforts create structural growth independent of economic conditions.
Moderate sensitivity through two channels: (1) Discount rate impact on valuation multiples - as a growth-oriented specialty pharma trading at 14.8x EV/EBITDA, rising rates compress multiples versus bonds; (2) Debt servicing costs on existing liabilities, though negative equity position suggests complex capital structure possibly involving legal settlements. Interest rate changes have minimal impact on underlying business operations or customer demand, as treatment decisions are clinically driven rather than financing-dependent.
Minimal direct credit exposure. Revenue primarily flows through government payers (Medicaid/Medicare) and large commercial insurers with strong credit profiles. Specialty pharmacy distribution partners carry minimal default risk. However, the company's own credit profile matters for refinancing existing obligations and funding legal settlements. Tightening credit conditions could constrain ability to invest in pipeline development or commercial expansion if capital markets access deteriorates.
growth - The 192.8% one-year return and 11,000%+ EPS growth (off depressed base) attract momentum and turnaround investors betting on Sublocade's commercial trajectory. Negative ROE and book value deter traditional value investors. High gross margins and operating leverage appeal to growth-at-reasonable-price (GARP) investors focused on earnings inflection. Lack of dividend and negative FCF eliminate income-focused buyers. The stock suits investors comfortable with binary legal/regulatory risks in exchange for exposure to structural addiction treatment market growth.
high - Specialty pharma stocks with concentrated product portfolios and legal overhangs exhibit elevated volatility. Patent litigation binary outcomes, regulatory decisions, and quarterly prescription volume surprises drive sharp price movements. The 36.3% six-month return followed by -0.9% three-month return demonstrates momentum reversals. Limited analyst coverage and $4.3B market cap create lower liquidity versus large-cap pharma, amplifying price swings on modest volume. Implied volatility likely trades above broad healthcare sector averages.